Biotech Showcase™, one of the largest biotech investor conferences in the world, presents this year’s conference agenda which highlights six therapeutic areas that are garnering investment interest in 2019. The event, held January 7-9, 2019 at the Hilton San Francisco Union Square, brings more than 3,600 decision makers from 2,200 biotech, financial, and pharma companies to network and share insights on industry trends through plenary sessions and panels. More than $330 billion in capital is expected to be represented by this year’s attendees.
“Biotech Showcase continues to be a pivotal forum for connecting biotechnology and pharmaceutical leaders with potential investors and partners to engage in discussions that drive the future of drug development,” said Sara Jane Demy, Founder and CEO, Demy-Colton.
“Over the last eleven years the event has built a reputation
for attracting companies and speakers that are leading the
way in revolutionizing healthcare and providing key insights
into industry trends that will shape the coming year.”
More than 900 investors from around the world are expected to attend, drawn to the estimated 400 public and private company presentations from international biotech companies ranging from public mid- and small-cap to private venture and angel-backed life science companies.
“During biotech’s biggest week, Biotech Showcase has become a strategic event that sets the tone for investing and collaboration over the next year,” said Anna Chrisman, Group Managing Director, EBD Group and KNect365 Life Sciences. “Life science leaders from across the globe gather at this event to hear from presenting companies and benefit from the workshops, insightful panels and plenary sessions, networking, and one-to-one meetings that facilitate impactful dealmaking activities.”
This year’s agenda includes a focus on six therapeutic areas that are seeing intriguing research, innovative technologies, and the promise of transforming the way diseases are treated across the globe. Biotech Showcase has assembled panels of high caliber speakers to discuss how advancements and investment in these areas will change the future of healthcare.
Alzheimer’s Disease – Reexamining Alzheimer’s: Is it a singular disease?
Panelists discuss what has been learned about Alzheimer’s and how this can inform better strategies for developing therapeutics going forward.
Moderator: Kim Goh, Principal at ClearView Healthcare Partners
Casey Lynch, CEO at Cortexyme
Kenneth I. Moch, President and CEO at Cognition Therapeutics, Inc.
John Vandermosten, Senior Biotech Analyst at Zacks
Barbara Tate, Chief Strategy Officer, Dementia Discovery Fund